Stephan Traidl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephan Traidl has a total of 409 co-authors. Here are the top co-authors by number of shared publications:
Thomas Werfel
30 shared publications- Lennart Matthias Roesner
Department of Dermatology and Allergy, Hannover Medical School
13 shared publications - Alexander Zink
Department of Dermatology and Allergy, School of Medicine Technical University of Munich Munich Germany
6 shared publications - Annice Heratizadeh
Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
6 shared publications - Stephan Weidinger
Center for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
6 shared publications - Susanne Abraham
Department of Dermatology, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Dresden, Germany; University Allergy Center (UAC), University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
6 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Dupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry
A distinct proportion of patients with atopic dermatitis and dupilumab treatment does not reach the primary endpoint of an eczema area severity index (EASI)-75 or investigator global assessment 0/1 after 16 weeks. Little is known about poor responders to dupilumab in real life scenarios. The study objective was to identify the percentage and characteristics of patients with insufficient treatment response to dupilumab based on “TREATgermany” registry data from dermatological routine care. Between 06/2016 and 12/2024, 476 patients matched the study criteria. In total, 4% of patients (n=19) were identified as dupilumab poor responders, i.e. reduction in EASI ≤40% at the 1st follow-up visit after 8 to 20 weeks and a consecutive 2nd follow-up visit up to 52 weeks of treatment. 44% (n=209) were classified as stable responders, i.e. decrease in EASI≥75% at both follow-up visits. Poor responders were significantly more often male, more frequently exhibited smoking, arterial hypertension and a higher body mass index. This TREATgermany data analysis demonstrates a proportion of 4% dupilumab poor responders within the first year of treatment. Male sex, smoking, arterial hypertension and increased body mass index were identified as potential risk factors. Further translational research is needed to confirm these clinical findings.
- 5 November 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessDupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry
A distinct proportion of patients with atopic dermatitis and dupilumab treatment does not reach the primary endpoint of an eczema area severity index (EASI)-75 or investigator global assessment 0/1 after 16 weeks. Little is known about poor responders to dupilumab in real life scenarios. The study objective was to identify the percentage and characteristics of patients with insufficient treatment response to dupilumab based on “TREATgermany” registry data from dermatological routine care. Between 06/2016 and 12/2024, 476 patients matched the study criteria. In total, 4% of patients (n=19) were identified as dupilumab poor responders, i.e. reduction in EASI ≤40% at the 1st follow-up visit after 8 to 20 weeks and a consecutive 2nd follow-up visit up to 52 weeks of treatment. 44% (n=209) were classified as stable responders, i.e. decrease in EASI≥75% at both follow-up visits. Poor responders were significantly more often male, more frequently exhibited smoking, arterial hypertension and a higher body mass index. This TREATgermany data analysis demonstrates a proportion of 4% dupilumab poor responders within the first year of treatment. Male sex, smoking, arterial hypertension and increased body mass index were identified as potential risk factors. Further translational research is needed to confirm these clinical findings.
- Open Access
Spatial Transcriptomics Identifies Characteristic Immunological Niches in Atopic Dermatitis
Background: Atopic dermatitis (AD) is primarily driven by a Type 2 immune response, with T helper (T H 2) cells producing IL‐4 and IL‐13, thereby promoting inflammation, itch, and a compromised skin barrier. Yet, the spatial organization of pathogenic immune cells and their interactions with stromal and epithelial compartments in human AD skin remain incompletely understood. Methods: We performed 10× Genomics Visium spatial transcriptomics on FFPE skin biopsies from patients with AD ( n = 6), psoriasis ( n = 2), and healthy controls ( n = 5). Data were integrated with AD single‐cell RNA sequencing (scRNA‐seq) datasets and complemented by imaging mass cytometry (IMC) and multiplex immunofluorescence (IF) to validate the spatial localization of immune cells. Cell–cell communication analysis revealed putative signaling interactions within immune niches. Results: Spatial clustering resolved tissue compartments and demonstrated transcriptional dysregulation in keratinocytes in AD and psoriasis. AD lesions showed a conserved spatial organization of immune aggregates within the superficial dermis. Integration of scRNA‐seq signatures revealed spatially organized co‐localization of T cells and mature migratory dendritic cells (mmDCs). We developed a ring‐based neighborhood analysis to characterize the cellular organization of the immune‐stromal niches, revealing T cell‐enriched regions surrounded by inflammatory fibroblasts and activated keratinocytes. Intercellular communication analysis further identified putative signaling within mmDC‐T cell niches that may promote pathogenic T cell recruitment and activation. Application of tertiary lymphoid structure (TLS) signatures indicated the presence of TLS‐like regions. IMC and IF validated the close spatial proximity between activated T H 2 cells and mmDCs. Conclusion: AD lesions contain spatially organized TLS‐like immune niches at the dermal‐epidermal junction, characterized by the close association of T cells and mmDCs and coordinated interactions with surrounding stromal and epithelial compartments. These mmDC‐T cell niches may represent potential targets for future therapeutic strategies aimed at disrupting persistent local inflammatory pathways and improving long‐term disease control.
Open AccessSpatial Transcriptomics Identifies Characteristic Immunological Niches in Atopic Dermatitis
Background: Atopic dermatitis (AD) is primarily driven by a Type 2 immune response, with T helper (T H 2) cells producing IL‐4 and IL‐13, thereby promoting inflammation, itch, and a compromised skin barrier. Yet, the spatial organization of pathogenic immune cells and their interactions with stromal and epithelial compartments in human AD skin remain incompletely understood. Methods: We performed 10× Genomics Visium spatial transcriptomics on FFPE skin biopsies from patients with AD ( n = 6), psoriasis ( n = 2), and healthy controls ( n = 5). Data were integrated with AD single‐cell RNA sequencing (scRNA‐seq) datasets and complemented by imaging mass cytometry (IMC) and multiplex immunofluorescence (IF) to validate the spatial localization of immune cells. Cell–cell communication analysis revealed putative signaling interactions within immune niches. Results: Spatial clustering resolved tissue compartments and demonstrated transcriptional dysregulation in keratinocytes in AD and psoriasis. AD lesions showed a conserved spatial organization of immune aggregates within the superficial dermis. Integration of scRNA‐seq signatures revealed spatially organized co‐localization of T cells and mature migratory dendritic cells (mmDCs). We developed a ring‐based neighborhood analysis to characterize the cellular organization of the immune‐stromal niches, revealing T cell‐enriched regions surrounded by inflammatory fibroblasts and activated keratinocytes. Intercellular communication analysis further identified putative signaling within mmDC‐T cell niches that may promote pathogenic T cell recruitment and activation. Application of tertiary lymphoid structure (TLS) signatures indicated the presence of TLS‐like regions. IMC and IF validated the close spatial proximity between activated T H 2 cells and mmDCs. Conclusion: AD lesions contain spatially organized TLS‐like immune niches at the dermal‐epidermal junction, characterized by the close association of T cells and mmDCs and coordinated interactions with surrounding stromal and epithelial compartments. These mmDC‐T cell niches may represent potential targets for future therapeutic strategies aimed at disrupting persistent local inflammatory pathways and improving long‐term disease control.
- Open Access
- 6 August 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry
Atopic dermatitis is commonly associated with depressive symptoms and fatigue, which significantly impact quality of life. While clinical trials suggest beneficial effects of dupilumab on mental health, real-world evidence remains limited. This longitudinal cohort study analysed data from adult patients treated with dupilumab in the TREATgermany registry. Subgroups were defined by baseline Center for Epidemiologic Studies Depression Scale (CES D) scores ≥16 (clinically significant depressive symptoms) and Fatigue Severity Scale (FSS) scores >4 (significant fatigue). Clinical severity (Eczema Area and Severity Index [EASI], objective Scoring Atopic Dermatitis [oSCORAD]), quality of life (DLQI), psychological symptoms, treatment needs and benefits (PNQ, PBI) and drug survival were assessed over 12 months. Among 633 patients, those with elevated baseline CES-D (n=309) or FSS (n=281) scores reported greater disease burden measured by DLQI, while EASI and oSCORAD did not differ between subgroups. Both CES-D and FSS scores decreased markedly within the first 3 months. Sleep and social functioning needs were more frequently reported in high-burden subgroups and more often fulfilled after 12 months. Drug survival was comparable across subgroups. Dupilumab treatment was associated with significant improvements in depressive symptoms, fatigue and skin severity. Patients with higher baseline mental health burden showed comparable improvements in patient relevant domains, supporting the broad relevance of dupilumab in real-world atopic dermatitis care.
- 6 August 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessImprovement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry
Atopic dermatitis is commonly associated with depressive symptoms and fatigue, which significantly impact quality of life. While clinical trials suggest beneficial effects of dupilumab on mental health, real-world evidence remains limited. This longitudinal cohort study analysed data from adult patients treated with dupilumab in the TREATgermany registry. Subgroups were defined by baseline Center for Epidemiologic Studies Depression Scale (CES D) scores ≥16 (clinically significant depressive symptoms) and Fatigue Severity Scale (FSS) scores >4 (significant fatigue). Clinical severity (Eczema Area and Severity Index [EASI], objective Scoring Atopic Dermatitis [oSCORAD]), quality of life (DLQI), psychological symptoms, treatment needs and benefits (PNQ, PBI) and drug survival were assessed over 12 months. Among 633 patients, those with elevated baseline CES-D (n=309) or FSS (n=281) scores reported greater disease burden measured by DLQI, while EASI and oSCORAD did not differ between subgroups. Both CES-D and FSS scores decreased markedly within the first 3 months. Sleep and social functioning needs were more frequently reported in high-burden subgroups and more often fulfilled after 12 months. Drug survival was comparable across subgroups. Dupilumab treatment was associated with significant improvements in depressive symptoms, fatigue and skin severity. Patients with higher baseline mental health burden showed comparable improvements in patient relevant domains, supporting the broad relevance of dupilumab in real-world atopic dermatitis care.
- Open Access
- 30 July 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Patient treatment needs in atopic dermatitis: A real‐world cohort study
Background: Atopic dermatitis (AD) substantially affects quality of life, yet standardized severity measures may not capture patient‐centred priorities, making systematic needs assessment essential for personalized care. Objectives: This study aimed to systematically assess and rank treatment needs in adults with moderate to severe AD, identify patient subgroups with distinct need profiles and evaluate how well these needs were met after 2 years of specialized dermatological care. Methods: In this prospective observational study from the TREATgermany registry, 697 adults with moderate to severe AD completed the validated Patient Benefit Index (PBI) at baseline (T1) and at 2‐year follow‐up (T2), capturing treatment goal importance and achievement. Subgroup analyses were performed based on age, sex, educational status and age at AD onset. Associations between clinical measures and perceived benefit were analysed. Results: The most frequently prioritized treatment goals were being free of itching (97.8% high agreement), regaining control of the disease (95.3%) and relief from skin burning (92.0%). The importance of itch reduction was not correlated with baseline pruritus intensity, and perceived benefit was more closely linked to relative clinical improvement than to absolute disease severity. Beyond these shared priorities, treatment needs varied across subgroups: older patients valued treatment safety and reduced dependence on medical care, women emphasized psychosocial and appearance‐related goals, individuals with lower educational status highlighted financial concerns and patients with adult‐onset AD prioritized diagnostic certainty and disease control. After 2 years, 96.6% of patients reported meaningful treatment benefit. Patient‐reported outcomes (POEM) were more strongly associated with perceived benefit than physician‐assessed measures (oSCORAD, EASI). Conclusion: Patient treatment needs in AD vary by demographic and clinical factors, with pruritus consistently rated as the highest priority. Patient‐reported outcomes align more closely with perceived benefit than physician assessments, underscoring the value of systematic needs assessments to guide individualized treatment decisions and shared decision‐making.
- 30 July 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Open AccessPatient treatment needs in atopic dermatitis: A real‐world cohort study
Background: Atopic dermatitis (AD) substantially affects quality of life, yet standardized severity measures may not capture patient‐centred priorities, making systematic needs assessment essential for personalized care. Objectives: This study aimed to systematically assess and rank treatment needs in adults with moderate to severe AD, identify patient subgroups with distinct need profiles and evaluate how well these needs were met after 2 years of specialized dermatological care. Methods: In this prospective observational study from the TREATgermany registry, 697 adults with moderate to severe AD completed the validated Patient Benefit Index (PBI) at baseline (T1) and at 2‐year follow‐up (T2), capturing treatment goal importance and achievement. Subgroup analyses were performed based on age, sex, educational status and age at AD onset. Associations between clinical measures and perceived benefit were analysed. Results: The most frequently prioritized treatment goals were being free of itching (97.8% high agreement), regaining control of the disease (95.3%) and relief from skin burning (92.0%). The importance of itch reduction was not correlated with baseline pruritus intensity, and perceived benefit was more closely linked to relative clinical improvement than to absolute disease severity. Beyond these shared priorities, treatment needs varied across subgroups: older patients valued treatment safety and reduced dependence on medical care, women emphasized psychosocial and appearance‐related goals, individuals with lower educational status highlighted financial concerns and patients with adult‐onset AD prioritized diagnostic certainty and disease control. After 2 years, 96.6% of patients reported meaningful treatment benefit. Patient‐reported outcomes (POEM) were more strongly associated with perceived benefit than physician‐assessed measures (oSCORAD, EASI). Conclusion: Patient treatment needs in AD vary by demographic and clinical factors, with pruritus consistently rated as the highest priority. Patient‐reported outcomes align more closely with perceived benefit than physician assessments, underscoring the value of systematic needs assessments to guide individualized treatment decisions and shared decision‐making.
- Open Access
- 7 July 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 934-953
Digitale Dermatologie
ZUSAMMENFASSUNG: Die digitale Transformation verändert die Dermatologie grundlegend und eröffnet neue Möglichkeiten in Diagnostik, Therapie und Versorgungsorganisation. Große Datenmengen in Kombination mit Künstlicher Intelligenz (KI) erlauben eine präzisere Klassifikation und Prognose, insbesondere durch die Analyse klinischer und dermatoskopischer Bilddaten. Zunehmend werden auch synthetisch generierte Daten für das Training neuer Algorithmen genutzt, deren klinische Validität noch geprüft werden muss. Teledermatologie hat sich als fester Bestandteil der Versorgung etabliert. Videokonsultationen und asynchrone Bildübertragungen verbessern die Erreichbarkeit dermatologischer Expertise und könnten insbesondere in strukturschwachen Regionen eine Versorgungslücke schließen. Mobile Anwendungen und digitale Plattformen fördern zudem Adhärenz, Selbstmonitoring und die aktive Beteiligung der Patientinnen und Patienten am Behandlungsprozess. Trotz dieser Chancen bestehen gleichzeitig auch große Herausforderungen. Datenschutz, Interoperabilität und regulatorische Rahmenbedingungen müssen adressiert werden, um eine nachhaltige Implementierung sicherzustellen. Entscheidend ist darüber hinaus die interdisziplinäre Zusammenarbeit zwischen Medizin, Technik und Gesundheitsökonomie. Dabei kommt Ärztinnen und Ärzte als Fachexperten eine zentrale Rolle zu, sowohl bei der Bewertung der Datenqualität als auch bei der klinischen Interpretation digitaler Systeme. Ebenso wichtig ist eine kontinuierliche Schulung des Fachpersonals. Insgesamt bietet die Digitalisierung ein großes Potenzial zur Verbesserung der dermatologischen Versorgung. Voraussetzung hierfür sind strukturierte Prozesse, Qualitätssicherung und die konsequente Einbindung von Patientinnen und Patienten.
- 7 July 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 934-953
Open AccessDigitale Dermatologie
ZUSAMMENFASSUNG: Die digitale Transformation verändert die Dermatologie grundlegend und eröffnet neue Möglichkeiten in Diagnostik, Therapie und Versorgungsorganisation. Große Datenmengen in Kombination mit Künstlicher Intelligenz (KI) erlauben eine präzisere Klassifikation und Prognose, insbesondere durch die Analyse klinischer und dermatoskopischer Bilddaten. Zunehmend werden auch synthetisch generierte Daten für das Training neuer Algorithmen genutzt, deren klinische Validität noch geprüft werden muss. Teledermatologie hat sich als fester Bestandteil der Versorgung etabliert. Videokonsultationen und asynchrone Bildübertragungen verbessern die Erreichbarkeit dermatologischer Expertise und könnten insbesondere in strukturschwachen Regionen eine Versorgungslücke schließen. Mobile Anwendungen und digitale Plattformen fördern zudem Adhärenz, Selbstmonitoring und die aktive Beteiligung der Patientinnen und Patienten am Behandlungsprozess. Trotz dieser Chancen bestehen gleichzeitig auch große Herausforderungen. Datenschutz, Interoperabilität und regulatorische Rahmenbedingungen müssen adressiert werden, um eine nachhaltige Implementierung sicherzustellen. Entscheidend ist darüber hinaus die interdisziplinäre Zusammenarbeit zwischen Medizin, Technik und Gesundheitsökonomie. Dabei kommt Ärztinnen und Ärzte als Fachexperten eine zentrale Rolle zu, sowohl bei der Bewertung der Datenqualität als auch bei der klinischen Interpretation digitaler Systeme. Ebenso wichtig ist eine kontinuierliche Schulung des Fachpersonals. Insgesamt bietet die Digitalisierung ein großes Potenzial zur Verbesserung der dermatologischen Versorgung. Voraussetzung hierfür sind strukturierte Prozesse, Qualitätssicherung und die konsequente Einbindung von Patientinnen und Patienten.
- Open Access
- 16 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , e934-e952
Digital Dermatology
SUMMARY: Digital transformation is fundamentally reshaping dermatology, creating new opportunities in diagnostics, therapy, and healthcare organization. Large datasets combined with Artificial Intelligence (AI) enable more precise classification and prognosis, particularly through the analysis of clinical and dermoscopic imaging. Increasingly, synthetically generated data is used to train new algorithms, though its clinical validity remains under evaluation. Teledermatology has established itself as an integral part of care. Video consultations and asynchronous image transfers enhance accessibility to dermatological expertise and can bridge care gaps, especially in structurally weak regions. Furthermore, mobile applications and digital platforms promote adherence, self‐monitoring, and active patient engagement. Despite these opportunities, challenges regarding data protection, interoperability, and regulatory frameworks must be addressed to ensure sustainable implementation. Interdisciplinary collaboration between medicine, technology, and health economics is crucial. Physicians play a central role as subject matter experts in assessing data quality and providing clinical interpretation of digital systems. Continuous training of medical staff remains essential. Overall, digitalization offers significant potential to improve dermatological care, provided there are structured processes, quality assurance, and consistent patient involvement.
- 16 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , e934-e952
Open AccessDigital Dermatology
SUMMARY: Digital transformation is fundamentally reshaping dermatology, creating new opportunities in diagnostics, therapy, and healthcare organization. Large datasets combined with Artificial Intelligence (AI) enable more precise classification and prognosis, particularly through the analysis of clinical and dermoscopic imaging. Increasingly, synthetically generated data is used to train new algorithms, though its clinical validity remains under evaluation. Teledermatology has established itself as an integral part of care. Video consultations and asynchronous image transfers enhance accessibility to dermatological expertise and can bridge care gaps, especially in structurally weak regions. Furthermore, mobile applications and digital platforms promote adherence, self‐monitoring, and active patient engagement. Despite these opportunities, challenges regarding data protection, interoperability, and regulatory frameworks must be addressed to ensure sustainable implementation. Interdisciplinary collaboration between medicine, technology, and health economics is crucial. Physicians play a central role as subject matter experts in assessing data quality and providing clinical interpretation of digital systems. Continuous training of medical staff remains essential. Overall, digitalization offers significant potential to improve dermatological care, provided there are structured processes, quality assurance, and consistent patient involvement.
- Open Access
Keratinocyte Priming by Staphylococcus aureus Reduces HSV ‐1 Susceptibility
Background: Individuals with atopic dermatitis (AD) are at increased risk for skin infections, including eczema herpeticum (EH), a severe condition caused by herpes simplex virus type 1 (HSV‐1). While AD skin is often colonized by Staphylococcus aureus ( S. aureus ), its role in EH susceptibility remains unclear. Here we aim to investigate differences in the skin microbiome of AD patients with (ADEH + ) and without (ADEH − ) EH and examine the impact of S. aureus and S. epidermidis on HSV‐1 infection in an in vitro keratinocyte model. Methods: 16S microbiome sequencing was performed on skin samples from ADEH + , ADEH − , and healthy controls. To investigate microbial effects on HSV‐1 infection, keratinocytes were pre‐incubated with heat‐killed S. aureus (HKSA) or S. epidermidis (HKSE), followed by HSV‐1 infection in the presence or absence of the Th2 cytokines IL‐4 and IL‐13, simulating the conditions of AD lesional skin. Infection rates and transcriptomic changes were analyzed. Results: ADEH + patients showed a reduced microbial diversity compared to ADEH − , with increased S. aureus and S. epidermidis colonization. HKSA, but not HKSE, protected keratinocytes from HSV‐1 infection and reduced the release of infectious progeny virus. Transcriptome analysis of keratinocytes revealed HKSA‐induced upregulation of interferon pathways and antimicrobial peptides, and downregulation of HSV‐1 entry factors. Conclusion: Pre‐incubation with S. aureus set basal keratinocytes into an alarmed state, restricting HSV‐1 infection presumably via downregulation of receptors important for viral entry and activation of antiviral pathways.
Open AccessKeratinocyte Priming by Staphylococcus aureus Reduces HSV ‐1 Susceptibility
Background: Individuals with atopic dermatitis (AD) are at increased risk for skin infections, including eczema herpeticum (EH), a severe condition caused by herpes simplex virus type 1 (HSV‐1). While AD skin is often colonized by Staphylococcus aureus ( S. aureus ), its role in EH susceptibility remains unclear. Here we aim to investigate differences in the skin microbiome of AD patients with (ADEH + ) and without (ADEH − ) EH and examine the impact of S. aureus and S. epidermidis on HSV‐1 infection in an in vitro keratinocyte model. Methods: 16S microbiome sequencing was performed on skin samples from ADEH + , ADEH − , and healthy controls. To investigate microbial effects on HSV‐1 infection, keratinocytes were pre‐incubated with heat‐killed S. aureus (HKSA) or S. epidermidis (HKSE), followed by HSV‐1 infection in the presence or absence of the Th2 cytokines IL‐4 and IL‐13, simulating the conditions of AD lesional skin. Infection rates and transcriptomic changes were analyzed. Results: ADEH + patients showed a reduced microbial diversity compared to ADEH − , with increased S. aureus and S. epidermidis colonization. HKSA, but not HKSE, protected keratinocytes from HSV‐1 infection and reduced the release of infectious progeny virus. Transcriptome analysis of keratinocytes revealed HKSA‐induced upregulation of interferon pathways and antimicrobial peptides, and downregulation of HSV‐1 entry factors. Conclusion: Pre‐incubation with S. aureus set basal keratinocytes into an alarmed state, restricting HSV‐1 infection presumably via downregulation of receptors important for viral entry and activation of antiviral pathways.
- Open Access
- 25 March 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (4) , 556-557
Paediatric psoriasis and biologics: An evidence gap in plain sight
- 25 March 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (4) , 556-557
Open AccessPaediatric psoriasis and biologics: An evidence gap in plain sight
- Open Access
- 3 March 2026
- Published by Wiley in JEADV Clinical Practice
The Role of Artificial Intelligence in Modern Allergology: A Review of Applications in Diagnosis, Prediction, and Management
Artificial Intelligence is rapidly transforming allergology by enhancing diagnosis, risk prediction, automation, patient communication, education, and therapy development. Machine learning approaches, including convolutional neural networks, recurrent architectures, and transformer‐based models, enable analysis of complex datasets from genomics, imaging, clinical records, and patient‐reported outcomes. Artificial Intelligence applications in atopic disease diagnosis demonstrate high accuracy in imaging‐based detection, molecular phenotyping, and acoustic monitoring, while unsupervised learning methods such as Uniform Manifold Approximation and Projection and Hierarchical Density‐Based Spatial Clustering of Applications with Noise reveal distinct sensitisation clusters and patient risk profiles. Predictive modelling facilitates individualised management, including outcome prediction for oral food challenges, stratification of drug hypersensitivity risk, and forecasting disease progression in asthma and atopic dermatitis. Artificial Intelligence‐driven automation, such as skin prick test quantification and pollen monitoring, improves reproducibility and efficiency in clinical workflows. Additionally, Artificial Intelligence‐guided approaches are being explored in allergen immunotherapy development, including epitope mapping and hypoallergenic vaccine design, supported by experimental validation using assays such as enzyme‐linked immunosorbent assay and basophil activation tests. Large language models like ChatGPT show potential for patient engagement and education, though limitations in clinical reasoning and safety necessitate supervised use. Despite promising results, most Artificial Intelligence applications remain at early stages, with challenges including dataset size, generalisability, interpretability, cost, and integration into routine practice. Prospective validation, multicenter studies, and ethical oversight are essential for safe and effective implementation. Overall, Artificial Intelligence holds significant potential to advance allergology toward a predictive, personalised, and preventive model of care, offering new tools for precision diagnostics, risk assessment, and therapeutic innovation.
- 3 March 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessThe Role of Artificial Intelligence in Modern Allergology: A Review of Applications in Diagnosis, Prediction, and Management
Artificial Intelligence is rapidly transforming allergology by enhancing diagnosis, risk prediction, automation, patient communication, education, and therapy development. Machine learning approaches, including convolutional neural networks, recurrent architectures, and transformer‐based models, enable analysis of complex datasets from genomics, imaging, clinical records, and patient‐reported outcomes. Artificial Intelligence applications in atopic disease diagnosis demonstrate high accuracy in imaging‐based detection, molecular phenotyping, and acoustic monitoring, while unsupervised learning methods such as Uniform Manifold Approximation and Projection and Hierarchical Density‐Based Spatial Clustering of Applications with Noise reveal distinct sensitisation clusters and patient risk profiles. Predictive modelling facilitates individualised management, including outcome prediction for oral food challenges, stratification of drug hypersensitivity risk, and forecasting disease progression in asthma and atopic dermatitis. Artificial Intelligence‐driven automation, such as skin prick test quantification and pollen monitoring, improves reproducibility and efficiency in clinical workflows. Additionally, Artificial Intelligence‐guided approaches are being explored in allergen immunotherapy development, including epitope mapping and hypoallergenic vaccine design, supported by experimental validation using assays such as enzyme‐linked immunosorbent assay and basophil activation tests. Large language models like ChatGPT show potential for patient engagement and education, though limitations in clinical reasoning and safety necessitate supervised use. Despite promising results, most Artificial Intelligence applications remain at early stages, with challenges including dataset size, generalisability, interpretability, cost, and integration into routine practice. Prospective validation, multicenter studies, and ethical oversight are essential for safe and effective implementation. Overall, Artificial Intelligence holds significant potential to advance allergology toward a predictive, personalised, and preventive model of care, offering new tools for precision diagnostics, risk assessment, and therapeutic innovation.
- Open Access
- 27 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0338451
Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study
Background: COVID-19 can have diverse clinical manifestations, ranging from asymptomatic infection to critical illness with multiorgan involvement. While many patients recover fully, others develop long-COVID, a heterogeneous condition marked by persistent symptoms beyond the acute phase. The immunological pathomechanisms between long-COVID and other post-acute recovery states remain unclear. Objective: To characterize and compare clinical, pulmonary, and proteomic profiles of patients with long-COVID (LC) and those recovering from severe COVID-19 without long-COVID (post-severe-COVID, PC), and to evaluate the predictive potential of machine learning–based biomarker analysis. Methods: In this monocentric, prospective observational study with a cross-sectional design, patients undergoing rehabilitation were included at admission. Clinical data, detailed symptom profiles, and lung function testing, including diffusing capacity of the lungs, were collected. Serum proteomics covering immune response and inflammation panels was performed, and a Random Forest classifier was applied to identify biomarkers differentiating LC and PC. Results: LC (n = 24) patients were younger (52 years vs. 58 years in PC), predominantly female (66.7% vs. 30.0% in PC), and reported fatigue, neurocognitive symptoms, and exercise intolerance, whereas PC (n = 40) patients showed greater pulmonary impairment, as shown by reduced diffusing capacity (46% vs. 72.5% in LC p <0.001). Proteomic profiling revealed distinct immune and inflammatory signatures between groups. Applying a random forest classification algorithm, we were able to distinguish between the LC and the PC group with a high degree of accuracy of around 89%, using LAMP3 (Lysosome-associated membrane glycoprotein 3), CKAP4 (cytoskeleton associated protein 4) and KRT19 (Keratin 19). Conclusions: This study introduces a novel characterization of patients recovering from severe COVID-19 without long-COVID, enabling clearer differentiation between persistent and recovering trajectories. Combining clinical data, pulmonary function, and proteomic machine learning analysis provides insight into post-acute COVID-19 biology and identifies candidate biomarkers for improved diagnosis.
- 27 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0338451
Open AccessDistinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study
Background: COVID-19 can have diverse clinical manifestations, ranging from asymptomatic infection to critical illness with multiorgan involvement. While many patients recover fully, others develop long-COVID, a heterogeneous condition marked by persistent symptoms beyond the acute phase. The immunological pathomechanisms between long-COVID and other post-acute recovery states remain unclear. Objective: To characterize and compare clinical, pulmonary, and proteomic profiles of patients with long-COVID (LC) and those recovering from severe COVID-19 without long-COVID (post-severe-COVID, PC), and to evaluate the predictive potential of machine learning–based biomarker analysis. Methods: In this monocentric, prospective observational study with a cross-sectional design, patients undergoing rehabilitation were included at admission. Clinical data, detailed symptom profiles, and lung function testing, including diffusing capacity of the lungs, were collected. Serum proteomics covering immune response and inflammation panels was performed, and a Random Forest classifier was applied to identify biomarkers differentiating LC and PC. Results: LC (n = 24) patients were younger (52 years vs. 58 years in PC), predominantly female (66.7% vs. 30.0% in PC), and reported fatigue, neurocognitive symptoms, and exercise intolerance, whereas PC (n = 40) patients showed greater pulmonary impairment, as shown by reduced diffusing capacity (46% vs. 72.5% in LC p <0.001). Proteomic profiling revealed distinct immune and inflammatory signatures between groups. Applying a random forest classification algorithm, we were able to distinguish between the LC and the PC group with a high degree of accuracy of around 89%, using LAMP3 (Lysosome-associated membrane glycoprotein 3), CKAP4 (cytoskeleton associated protein 4) and KRT19 (Keratin 19). Conclusions: This study introduces a novel characterization of patients recovering from severe COVID-19 without long-COVID, enabling clearer differentiation between persistent and recovering trajectories. Combining clinical data, pulmonary function, and proteomic machine learning analysis provides insight into post-acute COVID-19 biology and identifies candidate biomarkers for improved diagnosis.